Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy

NACompletedINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 8, 2020

Primary Completion Date

September 6, 2022

Study Completion Date

September 6, 2022

Conditions
Diabetes Mellitus, Type 2Glucose
Interventions
DEVICE

FreeStyle Libre Flash Glucose Monitor

The FreeStyle Libre FGM device consists of a skin-worn disposable sensor that automatically measures and continuously stores glucose readings. The sensor is placed by a single-use applicator and is activated by a wireless scan with a handheld reader. It is designed to stay on the body for up to 14 days, and can be worn under clothing. After a 1-hour warm-up period, the sensor takes automatic measurements of glucose every 15 minutes for up to 14 days. The device collects the interstitial glucose values and stores them for subsequent upload at the end of the 14-day wear period. With each scan, users receive their glucose reading; the last eight hours of glucose data; and an arrow illustrating the direction their glucose is heading.

OTHER

Diabetes self-management education

"The DSME curriculum is compromised of:~1. Review of weekly glucose report (Trend glucose report from Libreview for intervention group; and weekly glucose report in log book format from their glucose monitoring software for control group)~2. Education modules for both in-person and remote delivery;~3. Handouts to support the curriculum objectives; and~4. Blood glucose monitoring challenges to stimulate behaviour change and reinforce learning."

Trial Locations (6)

L6S 0C6

LMC Brampton, Brampton

M9R 4E1

LMC Etobicoke, Etobicoke

L6M 1M1

LMC Oakville, Oakville

K2J 0V2

LMC Ottawa, Ottawa

M4G 3E8

LMC Midtown, Toronto

L4K 4M2

LMC Vaughan/Thornhill, Vaughan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott Diabetes Care

INDUSTRY

lead

LMC Diabetes & Endocrinology Ltd.

OTHER

NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy | Biotech Hunter | Biotech Hunter